Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays.

ABSTRACT:

Background

A challenge for drug of abuse testing is presented by 'designer drugs', compounds typically discovered by modifications of existing clinical drug classes such as amphetamines and cannabinoids. Drug of abuse screening immunoassays directed at amphetamine or methamphetamine only detect a small subset of designer amphetamine-like drugs, and those immunoassays designed for tetrahydrocannabinol metabolites generally do not cross-react with synthetic cannabinoids lacking the classic cannabinoid chemical backbone. This suggests complexity in understanding how to detect and identify whether a patient has taken a molecule of one class or another, impacting clinical care.

Methods

Cross-reactivity data from immunoassays specifically targeting designer amphetamine-like and sy

SUBMITTER: Krasowski MD 

PROVIDER: S-EPMC4029917 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature